Brief: Lonza Raises 2026 Margin Outlook After Strong First Half
BRIEF-Lonza Raises 2026 Margin Outlook After Strong First Half July 22 (Reuters) - LONZA GROUP AG LONN.S:
LONZA H1 SALES CHF 3,400 MILLION
LONZA H1 CORE EBITDA CHF 1,200 MILLION
LONZA H1 SALES GROWTH 16%
H1 2026 CORE EBITDA CHF 1.20 BILLION, MARGIN 34.8%
H1 2026 SALES CHF 3.40 BILLION WITH 16.0% CER SALES GROWTH
H1 2026 FREE CASH FLOW CHF 0.40 BILLION
ANNOUNCES EXPANSION OF COMMERCIAL-SCALE ADC DRUG PRODUCT CAPACITY IN STEIN, SWITZERLAND
UPGRADES 2026 CORE EBITDA MARGIN OUTLOOK TO 33-34%
ANNOUNCES EXPANSION OF PAYLOAD-LINKER MANUFACTURING CAPACITY IN VISP, SWITZERLAND
FOR 2026, LONZA UPGRADES ITS CORE EBITDA MARGIN OUTLOOK TO 33-34% (PREVIOUSLY: ABOVE 32%) AND CONFIRMS ITS EXPECTATION FOR CER SALES GROWTH OF 11-12%.
LONZA EXPECTS PERFORMANCE IN H1 2026 TO SUPPORT ANOTHER STRONG FULL-YEAR RESULT
ASSUMING SPOT RATES OF MID-JULY 2026 PREVAIL THROUGH H2, LONZA ANTICIPATES A FX^4 GROWTH HEADWIND OF APPROXIMATELY -2 TO -3% ON SALES IN 2026.
Source text: ID:nEQ2WkppVa
Further company coverage: LONN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Lonza AG
See all newsLonza buys 5 sites from Germany's Merck to more than double US footprint (updated)
Brief: Merck KGaA Confirms Divestment Of CDMO Business To Lonza
Lonza agrees to buy five US sites from Merck KGaA
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Table: Swiss trade surplus at CHF 1.31 bln in September